
Mission Statement
MitoRx Therapeutics’ first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases, focusing internally on 3 rare indications and partnering on broader indications.
Based in Oxford and Exeter, UK, MitoRx is developing a pipeline of pre-clinical programs to progress to the clinic. Built around the pioneer of mitochondrial-targeted sulfide donor technology, Prof Matt Whiteman PhD, the team is specialized in rare diseases acceleration and IP strategy.
MitoRx Therapeutics’ MTRX technology is based on over a decade’s work, and over twenty publications demonstrating pharmacological utility in multiple in vivo models.
On the web
Website: https://www.mitorxtherapeutics.com/